The U.S. Food and Drug Administration has delayed reviews of two drugs chosen for the Trump administration's new fast-track ...
The U.S. Food and Drug Administration has delayed reviews of several drugs selected for the Trump administrations new ...
FDA delays drug reviews for two priority voucher drugs amid safety and efficacy concerns, extending timelines for Sanofi and Disc Medicine products.
U.S. regulators will begin offering faster reviews to new medicines that administration officials deem as promoting “the health interests of Americans,” under a new initiative announced Tuesday. Food ...
People with type 2 diabetes who receive comprehensive medication reviews (CMRs) had better adherence with oral antidiabetic drugs and statin utilization compared to those who did not receive CMRs, a ...
WASHINGTON (AP) — U.S. regulators will begin offering faster reviews to new medicines that administration officials deem as promoting “the health interests of Americans,” under a new initiative ...